How to Optimize the Effectiveness and Safety of Parkinson's Disease Therapy? - A Systematic Review of Drugs Interactions with Food and Dietary Supplements
- PMID: 34784871
- PMCID: PMC9881082
- DOI: 10.2174/1570159X19666211116142806
How to Optimize the Effectiveness and Safety of Parkinson's Disease Therapy? - A Systematic Review of Drugs Interactions with Food and Dietary Supplements
Abstract
Background: Despite increasing worldwide incidence of Parkinson's disease, the therapy is still suboptimal due to the diversified clinical manifestations, lack of sufficient treatment, the poor adherence in advanced patients, and varied response. Proper intake of medications regarding food and managing drug-food interactions may optimize Parkinson's disease treatment.
Objectives: We investigated potential effects that food, beverages, and dietary supplements may have on the pharmacokinetics and pharmacodynamics of drugs used by parkinsonian patients; identified the most probable interactions; and shaped recommendations for the optimal intake of drugs regarding food.
Methods: We performed a systematic review in adherence to PRISMA guidelines, and included a total of 81 studies in the qualitative synthesis.
Results and conclusion: We found evidence for levodopa positive interaction with coffee, fiber and vitamin C, as well as for the potential beneficial impact of low-fat and protein redistribution diet. Contrastingly, high-protein diet and ferrous sulfate supplements can negatively affect levodopa pharmacokinetics and effectiveness. For other drugs, the data of food impact are scarce. Based on the available limited evidence, all dopamine agonists (bromocriptine, cabergoline, ropinirole), tolcapone, rasagiline, selegiline in tablets, safinamide, amantadine and pimavanserin can be taken with or without a meal. Opicapone and orally disintegrating selegiline tablets should be administered on an empty stomach. Of monoamine oxidase B inhibitors, safinamide is the least susceptible for interaction with the tyramine-rich food, whereas selegiline and rasagiline may lose selectivity to monoamine oxidase B when administered in supratherapeutic doses. The level of presented evidence is low due to the poor studies design, their insufficient actuality, and missing data.
Keywords: Parkinson; fiber; food; interaction; levodopa; meal; protein.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Figures
Similar articles
-
Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.Eur J Clin Pharmacol. 2020 Dec;76(12):1731-1743. doi: 10.1007/s00228-020-02961-6. Epub 2020 Jul 24. Eur J Clin Pharmacol. 2020. PMID: 32710141 Free PMC article.
-
Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.Expert Rev Neurother. 2005 Nov;5(6):811-21. doi: 10.1586/14737175.5.6.811. Expert Rev Neurother. 2005. PMID: 16274338 Review.
-
A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.Br J Clin Pharmacol. 2018 Sep;84(9):1917-1927. doi: 10.1111/bcp.13651. Epub 2018 Jun 25. Br J Clin Pharmacol. 2018. PMID: 29847694 Free PMC article.
-
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.Eur J Neurol. 2023 Apr;30(4):1118-1134. doi: 10.1111/ene.15651. Epub 2022 Dec 11. Eur J Neurol. 2023. PMID: 36437702 Review.
-
Medical management of levodopa-associated motor complications in patients with Parkinson's disease.CNS Drugs. 2007;21(8):677-92. doi: 10.2165/00023210-200721080-00005. CNS Drugs. 2007. PMID: 17630819 Review.
Cited by
-
Management of dysphagia and gastroparesis in Parkinson's disease in real-world clinical practice - Balancing pharmacological and non-pharmacological approaches.Front Aging Neurosci. 2022 Aug 11;14:979826. doi: 10.3389/fnagi.2022.979826. eCollection 2022. Front Aging Neurosci. 2022. PMID: 36034128 Free PMC article. Review.
-
Parkinson's drug starves gut microbes of iron.Nat Microbiol. 2024 Dec;9(12):3090-3092. doi: 10.1038/s41564-024-01863-y. Nat Microbiol. 2024. PMID: 39578576 No abstract available.
-
Antiparkinsonian Medication Reconciliation as a Strategy to Improve Safety by Preventing Medication Errors.Mov Disord Clin Pract. 2023 May 23;10(7):1090-1098. doi: 10.1002/mdc3.13789. eCollection 2023 Jul. Mov Disord Clin Pract. 2023. PMID: 37476316 Free PMC article.
-
Assessment of body composition, sarcopenia and protein intake in mild to moderate Parkinson's disease.Front Nutr. 2025 Jul 7;12:1507545. doi: 10.3389/fnut.2025.1507545. eCollection 2025. Front Nutr. 2025. PMID: 40693199 Free PMC article.
-
Errors Associated With Medication Administration by a Nurse During Hospitalisation: A Prospective Observational Multicentric Study.Nurs Open. 2025 Jan;12(1):e70139. doi: 10.1002/nop2.70139. Nurs Open. 2025. PMID: 39793977 Free PMC article.
References
-
- Up To Date: Clinical manifestations of Parkinson disease. Available from: https://www.uptodate.com/contents/clinical-manifesta-tions-of-parkinson-... (Accessed Mar 16, 2021).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical